BIOCON:NSE-Biocon Limited (INR)

COMMON STOCK | Biotechnology | NSE

Last Closing Price

INR 319.90

Change

-6.25 (-1.92)%

Market Cap

INR 382.50B

Volume

1.44M

Avg Analyst Target

INR 385.57 (+20.53%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Biocon Limited (BIOCON) Stock Analysis:
Based on the Biocon Limited stock forecasts from 5 analysts, the average analyst target price for Biocon Limited is INR 385.57 over the next 12 months. Biocon Limited’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Biocon Limited is Neutral, which is based on 6 positive signals and 7 negative signals. At the last closing, Biocon Limited’s stock price was INR 319.90. Biocon Limited’s stock price has changed by -5.51% over the past week, -8.78% over the past month and -17.72% over the last year.

About

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology ...Read More

Company Website : https://www.biocon.com

Address : 20th KM, Hosur Road, Bengaluru, India, 560100

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.60

52 Week High : 420.25

52 Week Low : 314.80

200 Day Moving Average : 359.32

50 Day Moving Average : 347.47

Shares Held By Insiders : 65.76%

Shares Held by Institutions : 15.35%

Dividend Yield : 0.15%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SYNGENE:NSE Syngene International Limited

+6.90 (+1.31%)

 INR217.41B 55.02 25.54
JUBLINGREA:NSE Jubilant Ingrevia Limited

+32.65 (+7.54%)

 INR70.77B 21.37 17.03
DCAL:NSE Dishman Carbogen Amcis Limited

-2.60 (-2.20%)

 INR17.93B 62.91 7.11
PANACEABIO:NSE Panacea Biotec Limited

+0.75 (+0.54%)

 INR8.48B 18.52 53.05
ZOTA:NSE Zota Health Care LImited

+3.30 (+1.22%)

 INR6.62B 72.23 41.40
LYKALABS:NSE Lyka Labs Limited

+6.40 (+4.99%)

 INR3.86B 7.04 5.03
TAKE:NSE Take Solutions Limited

+0.75 (+3.37%)

 INR3.31B 4.82 34.07
SMSLIFE:NSE SMS Lifesciences India Limited

+39.10 (+6.93%)

 INR1.83B 8.60 5.31
CELESTIAL:NSE Celestial Biolabs Limited

N/A

 INR0.05B 1.09 1.45

ETFs Containing BIOCON

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.27% 100% A+ 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.27% 100% A+ 48% F
Trailing 12 Months  
Capital Gain -17.08% 50% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.08% 50% F 16% F
Trailing 5 Years  
Capital Gain 93.27% 67% D+ 76% C
Dividend Return 0.91% 67% D+ 12% F
Total Return 94.18% 67% D+ 76% C
Average Annual (5 Year Horizon)  
Capital Gain 19.09% 56% F 55% F
Dividend Return 0.11% 50% F 5% F
Total Return 19.20% 56% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 38.68% 67% D+ 72% C-
Risk Adjusted Return 49.62% 67% D+ 73% C
Market Capitalization 382.50B 100% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 58.73 30% F 16% F
Price/Book Ratio 4.64 40% F 24% F
Price / Cash Flow Ratio 32.51 44% F 20% F
EV/EBITDA 21.94 50% F 27% F
Management Effectiveness  
Return on Equity 8.58% 78% C+ 44% F
Return on Invested Capital 3.06% 50% F 36% F
Return on Assets 4.40% 67% D+ 53% F
Debt to Equity Ratio 47.42% 11% F 24% F
Technical Ratios  
Dividend Yield 0.15% 43% F 6% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.60 89% B+ 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.